Ross Osborn
Stock Analyst at Cantor Fitzgerald
(2.13)
# 2,910
Out of 5,124 analysts
119
Total ratings
36.36%
Success rate
-1.89%
Average return
Main Sectors:
Stocks Rated by Ross Osborn
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CVRX CVRx, Inc. | Maintains: Overweight | $11 → $13 | $7.67 | +69.49% | 4 | Nov 6, 2025 | |
| PRE Prenetics Global | Maintains: Overweight | $26 → $32 | $15.85 | +101.89% | 8 | Oct 29, 2025 | |
| ORGO Organogenesis Holdings | Maintains: Overweight | $7 → $9 | $4.41 | +104.08% | 4 | Aug 8, 2025 | |
| LMAT LeMaitre Vascular | Maintains: Neutral | $92 → $95 | $81.91 | +15.98% | 2 | Aug 6, 2025 | |
| SIBN SI-BONE | Reiterates: Overweight | $25 | $19.97 | +25.19% | 10 | Aug 5, 2025 | |
| MDXG MiMedx Group | Maintains: Overweight | $11 → $12 | $6.33 | +89.57% | 5 | Jul 31, 2025 | |
| BVS Bioventus | Initiates: Overweight | $12 | $7.57 | +58.52% | 1 | Jul 7, 2025 | |
| XGN Exagen | Maintains: Overweight | $8 → $7 | $5.95 | +17.65% | 6 | May 15, 2025 | |
| LUCD Lucid Diagnostics | Reiterates: Overweight | $2 | $1.13 | +76.99% | 6 | May 15, 2025 | |
| NPCE NeuroPace | Reiterates: Overweight | $17 | $15.86 | +7.19% | 7 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $9 | $3.02 | +198.01% | 11 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $46 | $23.56 | +95.25% | 6 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $8 | $0.61 | +1,202.93% | 10 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $24 | $31.76 | -24.43% | 3 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $4 | $2.05 | +95.12% | 4 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $9 | $4.78 | +88.28% | 1 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $21 | $3.47 | +505.19% | 10 | Dec 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $16 | $4.70 | +240.43% | 4 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3.5 | $1.98 | +76.77% | 5 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $2.5 | $0.28 | +792.54% | 3 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $1.27 | - | 7 | Apr 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $258 | $7.35 | +3,414.29% | 2 | Aug 18, 2023 |
CVRx, Inc.
Nov 6, 2025
Maintains: Overweight
Price Target: $11 → $13
Current: $7.67
Upside: +69.49%
Prenetics Global
Oct 29, 2025
Maintains: Overweight
Price Target: $26 → $32
Current: $15.85
Upside: +101.89%
Organogenesis Holdings
Aug 8, 2025
Maintains: Overweight
Price Target: $7 → $9
Current: $4.41
Upside: +104.08%
LeMaitre Vascular
Aug 6, 2025
Maintains: Neutral
Price Target: $92 → $95
Current: $81.91
Upside: +15.98%
SI-BONE
Aug 5, 2025
Reiterates: Overweight
Price Target: $25
Current: $19.97
Upside: +25.19%
MiMedx Group
Jul 31, 2025
Maintains: Overweight
Price Target: $11 → $12
Current: $6.33
Upside: +89.57%
Bioventus
Jul 7, 2025
Initiates: Overweight
Price Target: $12
Current: $7.57
Upside: +58.52%
Exagen
May 15, 2025
Maintains: Overweight
Price Target: $8 → $7
Current: $5.95
Upside: +17.65%
Lucid Diagnostics
May 15, 2025
Reiterates: Overweight
Price Target: $2
Current: $1.13
Upside: +76.99%
NeuroPace
May 14, 2025
Reiterates: Overweight
Price Target: $17
Current: $15.86
Upside: +7.19%
Apr 1, 2025
Maintains: Overweight
Price Target: $12 → $9
Current: $3.02
Upside: +198.01%
Mar 26, 2025
Reiterates: Overweight
Price Target: $46
Current: $23.56
Upside: +95.25%
Mar 7, 2025
Reiterates: Overweight
Price Target: $8
Current: $0.61
Upside: +1,202.93%
Mar 5, 2025
Reiterates: Overweight
Price Target: $24
Current: $31.76
Upside: -24.43%
Feb 21, 2025
Reiterates: Overweight
Price Target: $4
Current: $2.05
Upside: +95.12%
Jan 7, 2025
Initiates: Overweight
Price Target: $9
Current: $4.78
Upside: +88.28%
Dec 24, 2024
Reiterates: Overweight
Price Target: $21
Current: $3.47
Upside: +505.19%
Nov 5, 2024
Reiterates: Overweight
Price Target: $16
Current: $4.70
Upside: +240.43%
Aug 8, 2024
Reiterates: Overweight
Price Target: $3.5
Current: $1.98
Upside: +76.77%
May 16, 2024
Reiterates: Overweight
Price Target: $2.5
Current: $0.28
Upside: +792.54%
Apr 12, 2024
Reiterates: Neutral
Price Target: n/a
Current: $1.27
Upside: -
Aug 18, 2023
Reiterates: Neutral
Price Target: $258
Current: $7.35
Upside: +3,414.29%